Announcement time of this financial report: 2023-10-27 19:29:32
Haileel (stock code: 603639) is an enterprise focusing on R&D, production and sales of pesticide formulations, pesticide intermediates, pesticide raw materials, and water-soluble fertilizers. The company's main business includes pesticide formulations such as pesticides, fungicides, and herbicides, as well as pesticide raw materials such as imidacloprid, imidacloprid, and pyrazole ether. In addition, the company also produces water-soluble fertilizers containing amino acids and water-soluble fertilizers with a large number of elements.
In terms of assets and liabilities, Haileer's total assets at the end of the third quarter of 2023 were 6.401 billion yuan, up 9.65% from 5.838 billion yuan at the end of the previous year. Total liabilities were $3.05 billion, up 16.16% from $2,626 million at the end of the previous year, and net assets were $3.351 billion, up 4.33% from $3,212 billion at the end of the previous year. The balance ratio was 47.65%, up from 44.98% at the end of the previous year.
In terms of profit, Haileer's operating income for the third quarter of 2023 was 3.707 billion yuan, a slight decrease from 3.803 billion yuan in the same period last year, a decrease of 2.51%. Operating profit was 515 million yuan, a slight decrease from 525 million yuan in the same period last year, or 1.9%. Operating costs were 2,554 billion yuan, down 7.7% from 2,767 million yuan in the same period last year. This shows that the company has improved in cost control. Net profit was 442 million yuan, an increase of 2.56% compared to 431 million yuan in the same period last year, showing the company's steady profitability.
In terms of cash flow, Haileer's net cash flow from operating activities in the third quarter of 2023 was 579 million yuan, an increase of 90.99% compared to the 303 million yuan in the same period last year. This is a very positive sign indicating that the company's cash inflow from operating activities has increased significantly. This is mainly due to the company's timely return of sales payments.
In summary, Haileer's business conditions in the third quarter of 2023 were generally stable. Despite an increase in the balance ratio, net profit continued to grow steadily and cash flow improved markedly, all of which indicate that the company is doing well. In the future, Haileer will implement a two-wheel drive strategy, that is, integrated development of original drugs and formulations, and simultaneous domestic and foreign layout, which will help the company further enhance its competitiveness.
For investors, Haileer's steady financial situation and significant improvement in cash flow from operating activities are all highlights worth paying attention to. But at the same time, investors also need to pay attention to the rise in the company's balance ratio, as well as the slight decline in operating income and operating profit. Generally speaking, Haileel is a company worthy of investors' attention, but investors also need to fully consider the company's financial indicators when investing.
This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.